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OBJECTIVE — To use bone marrow transplantation (BMT) as a model for testing the asso-
ciation between hyperglycemia and infection.
RESEARCH DESIGN AND METHODS — This cohort study included 382 adults
(6.5% with diabetes) who had no evidence of infection before neutropenia during BMT. Mean
glucose was calculated from central laboratory and bedside measurements taken before neutro-
penia; the primary outcome was neutropenic infections.
RESULTS — Eighty-fourpatients(22%)developedatleastoneneutropenicinfection,includ-
ing 51 patients (13%) with bloodstream infections. In patients who did not receive glucocorti-
coids during neutropenia, each 10 mg/dl increase in mean preneutropenia glucose was
associated with an odds ratio of 1.08 (95% CI 0.98–1.19) (P  0.14) for any infection and
1.15 (1.03–1.28) (P  0.01) for bloodstream infections, after adjusting for age, sex, race,
year, cancer diagnosis, transplant type, and total glucocorticoid dose before neutropenia. In
those who received glucocorticoids during neutropenia (n  71), the adjusted odds ratio
associated with a 10 mg/dl increase in mean glucose was 1.21 (1.09–1.34) (P  0.0001) for
any infection and 1.24 (1.11–1.38) (P  0.0001) for bloodstream infections. There was no
association between mean glycemia and long length of hospital stay, critical status designa-
tion, or mortality.
CONCLUSIONS — In a BMT population highly susceptible to infection, there was a con-
tinuous positive association between mean antecedent glycemia and later infection risk, partic-
ularlyinpatientswhoreceivedglucocorticoidswhileneutropenic.Tightglycemiccontrolduring
BMT and glucocorticoid treatment may reduce infections.
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O
bservational studies in a variety of
inpatient populations suggest that
hyperglycemiaisassociatedwithan
increased prevalence of nosocomial in-
fections (1–4). However, in many such
studies, the study design leaves open
the possibility that hyperglycemia was
the consequence and not the cause of
the infections.
Patients undergoing bone marrow
transplantation (BMT) constitute an ex-
cellent study population for using ob-
servational data to evaluate whether
inpatient hyperglycemia predicts infec-
tions. During BMT, infection-free pa-
tients are rendered neutropenic, after
which they are at risk for developing
infections. Additionally, in-hospital
glycemiacanbeassessedforoveraweek
before the onset of neutropenia, allow-
ing for an unbiased estimate of a pa-
tient’s glycemic status.
BMT is also a good setting to explore
the impact of glucocorticoid use on the
relationship between hyperglycemia
and infections, since some but not all
patients receive glucocorticoids during the
neutropenic period for treatment of graft-
versus-host disease. Glucocorticoid treat-
ment for graft-versus-host disease during
BMT has been associated with increased in-
fections (5), an association that could be
mediated,atleastinpart,byglucocorticoid-
induced hyperglycemia.
In this study, we analyze data from
patients undergoing BMT at the Johns
Hopkins Sidney Kimmel Cancer Center
between 2002 and 2006 to determine
whether hyperglycemia before neutrope-
niaonsetincreasestheriskofinfection,as
well as long length of stay, critical status
designation, and in-hospital mortality.
RESEARCH DESIGN AND
METHODS— Adult patients who un-
derwent allogeneic or autologous BMT at
the Johns Hopkins Sidney Kimmel Can-
cer Center between 1 November 2002
and 1 November 2006 were identiﬁed
from a database. Of 449 records for re-
view, 67 patients were excluded because
neutropenia (absolute neutrophil count
500/mm
3) occurred within 2 days of
hospital admission (n  32), neutropenia
did not develop at all during the hospital-
ization (n  6), or an infection was diag-
nosed before the onset of neutropenia
(n  29). The remaining 382 patients be-
came the subjects of our study.
Each subject’s age, sex, race, cancer
diagnosis, BMT protocol used, and admis-
sion and discharge dates were obtained
through the hospital billing database. The
presence or absence of diabetes before hos-
pital admission was determined by investi-
gator review of the admission note and the
list of home medications. The date of neu-
tropenia onset was deﬁned as the date dur-
ing hospitalization when the absolute
neutrophil count fell to 500/mm
3.
Glycemic assessment
Oursubjectshadatotalof20,026glucose
measurementsduringtheirhospitalstays,
which were downloaded from available
databases, including results measured by
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via point-of-care testing (n  2,887).
Central laboratory glucose measure-
ments, available for 100% of the cohort,
weretypicallyperformeddailyintheearly
morning (between 12 and 3 A.M.). Capil-
lary point-of-care glucose, available for
34% of the cohort, was routinely mea-
sured in patients with actual or suspected
hyperglycemia;whenordered,itwasusu-
ally performed by the nursing staff four
times per day (before meals and at bed-
time). The point-of-care glucose meter
converted capillary glucose results to
plasma glucose equivalents. If two glu-
cose results were recorded for a single pa-
tient within 1 h, the latter result was
excluded in order to avoid introducing
bias from repeated testing of extreme glu-
cose readings (n  900). The primary ex-
posure variable, mean glycemia between
admission and neutropenia, was calcu-
lated for each patient by averaging all eli-
gible glucose values measured between
admission and 8 A.M. on the date of neu-
tropenia. A secondary analysis was per-
formed, in which preneutropenia mean
glucose was calculated from central labo-
ratory values only.
Clinical outcomes
Before the collection of patients’ glucose
records, the investigators abstracted clin-
ical outcomes using the electronic patient
record,whichholdsalllaboratory,micro-
biology,andradiographicdata.Clinicians
routinely monitor patients closely for in-
fections during the neutropenic period.
Infections were included if they occurred
between the onset of neutropenia and
hospital discharge. The deﬁnition of
bloodstream infection was one positive
blood culture (two, in the case of
coagulase-negative Staphylcoccus). Uri-
nary tract infection required a positive
urine culture with 100,000 colonies.
Pneumonia was deﬁned as a new inﬁl-
trateonachestradiographorcomputed
tomography scan and either a positive
sputum culture or information in the
discharge summary indicating clinical im-
provement with antibiotic treatment. Si-
nusitis was diagnosed if there was
computed tomography evidence of a si-
nus infection and documentation that the
medical team suspected the infection was
pathogenic. Finally, Clostridium difﬁcile
colitis was deﬁned as stool toxin positiv-
ity. A subject was deemed as having “any
infection” if any one of these infections
wasdiagnosedintheperiodbetweenneu-
tropenia and discharge.
Other outcomes collected from the
electronic record were hospital length of
stay (days between admission and dis-
charge or death) and mortality during
hospitalization. Finally, critical status
designationwasrecordedfromtheoncol-
ogy center database and was deﬁned as
the need for arterial line monitoring,
Swan-Ganz catheterization, continuous
venovenous hemodialysis, or intubation
during the hospital admission.
Statistical analysis
Mean glucose results for subgroups were
reported as median and interquartile
range (25th to 75th percentile) because
theirdistributionswerenonnormal.Non-
parametric methods, the Wilcoxon rank-
sumtest,andtheKruskal-Wallistestwere
used to test the null hypothesis of no dif-
ference in mean glycemia between two
subgroups and among multiple sub-
groups, respectively.
Analyseswereconductedusingapro-
spective approach, in which the indepen-
dent variable was mean glucose and the
dependent variable was infection. Based
on nonparametric graphs (using Lowess
Smoother techniques) that demonstrated
a continuous relationship between mean
preneutropenia glucose and the probabil-
ityofneutropenicinfections,ratherthana
threshold effect, mean preneutropenia
glycemiawastreatedasacontinuousvari-
ableintheanalysis.Multiplelogisticregres-
sion was used to test the null hypothesis of
no association against the alternative of a
linear relationship between inpatient gly-
cemia and the log odds of infection, after
controlling for potential confounders in-
cluding age, sex, race, type of cancer,
BMT type, and cumulative glucocorticoid
dose given before neutropenia. Because
glucocorticoids could exacerbate both hy-
perglycemia and infection risk, we tested
whether glucocorticoid use during neu-
tropenia modiﬁes the effect of mean gly-
cemia on infections. Multiple logistic
regression was also used to evaluate the
effect of hyperglycemia on the dichoto-
mous outcomes long length of stay (de-
ﬁned as 75th percentile or 28 days),
criticalstatusdesignation,andin-hospital
mortality.
RESULTS
Patient characteristics
Neutropenia developed after a mean of
9.3 days after admission. Subjects had a
medianof11(range4–177)glucoseread-
ings during the preneutropenic period,
and the median of subjects’ average pre-
neutropenia glucose was 108 mg/dl (83–
255). Approximately half the patients
were aged 50 years and had signiﬁ-
cantly lower mean preneutropenia glu-
cosethanthoseaged50years(Table1).
Few patients (6.5%) had a history of dia-
betes, and the median of these patients’
meanpreneutropeniaglucosewas172vs.
107 mg/dl in the group without diabetes.
Nearly half of the patients underwent
BMT for non-Hodgkins lymphoma, and
themajorityhadanautologoustransplan-
tation. There was no statistically signiﬁ-
cant difference in mean preneutropenia
glucose across diagnoses or transplant
types.Thevastmajorityofpatients(94%)
received some glucocorticoids during the
preneutropenic period, with the most
typical regimen being 20 mg/day dexa-
methasone on hospital days 5–8 (re-
ceived by 63% of patients). However,
glucocorticoid use during neutropenia
was less common, with only 71 subjects
(19%) receiving any glucocorticoids dur-
ing this period. Those treated received a
meandoseof16mgofdexamethasonefor
an average of 9.5 days.
Neutropenic infections and other
adverse outcomes
After neutropenia developed, 84 patients
(22%)hadatleastonedocumentedinfec-
tion(Table2).Bloodstreaminfectionswere
most common, occurring in 51 patients
(13%). Thirty-four (67%) bloodstream
infections were due to gram-negative
organisms,16(31%)togram-positiveor-
ganisms, and one to a fungal pathogen.
The most frequent bacteria cultured were
E. coli (n  17), coagulase negative Staph-
ylococcus(n9),andPseudomonasaerogi-
nosa (n  7). The diagnosis of infection
was made an average (SD) of 9.0  9.1
days after neutropenia developed, sup-
porting the notion that they were new,
not previously established, infections.
The mean length of stay was 26.1 
9.7 days. Critical status was designated
for only 15 patients (4%), for reasons in-
cluding intubation (n  12), need for ar-
terial monitoring (n  7), continuous
venovenous hemodialysis (n  3), and
pulmonary artery catheterization (n  1).
Thirteen patients (3%) died during their
hospital stay. In an unadjusted analysis,
there was a statistically signiﬁcant differ-
ence in mean preneutropenia glucose be-
tween affected and nonaffected patients
fortheoutcomesanyinfectionandblood-
stream infections (P  0.014 and P 
0.007, respectively) but not for other
Derr and Associates
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critical status, and in-hospital death (Ta-
ble 2).
Independent effect of hyperglycemia
on infection risk
After adjusting for age, sex, race, cancer
type, transplant type, year of transplant,
andtotalglucocorticoiddosereceivedbe-
fore neutropenia, antecedent hyperglyce-
mia was signiﬁcantly associated with an
increased rate of infection. The odds ratio
for any infection was 1.11 (95% CI 1.01–
1.21) (P  0.023) for every 10 mg/dl in-
crease in mean preneutropenia glycemia
(Table 3). This relationship between
mean glucose and neutropenic infections
wasmodiﬁedbyglucocorticoidtreatment
during neutropenia. For every 10 mg/dl
increase in mean preneutropenia glucose,
the odds ratio for any infection in 311
patients who did not receive glucocorti-
coids while neutropenic was 1.08 (0.98–
1.19)(P0.136),whereastheoddsratio
in 71 patients who did receive steroids
was 1.21 (1.09–1.33) (P  0.00001).
Figure 1A depicts the results of applying
our multivariate logistic regression model
for a subject with the most frequently en-
counteredcharacteristics.Inpatientswho
received glucocorticoids during neutro-
penia, a preneutropenia mean glucose of
200 vs. 100 mg/dl was associated with a
6.5 times higher (95% CI 2.0–21.2) risk
of infection.
The adjusted odds ratio associated
with a 10 mg/dl increase in mean preneu-
tropenia glycemia was even higher for
bloodstreaminfectionsthanforanyinfec-
tion, at 1.17 (95% CI 1.06–1.30) (P 
0.002) (Table 3). Effect modiﬁcation by
glucocorticoids was also signiﬁcant for
bloodstream infection, with an odds ratio
of1.15(1.03–1.28)(P0.010)and1.24
(1.11–1.38) (P  0.00001) associated
with every 10 mg/dl increment in mean
preneutropenia glucose for patients who
did not and did receive glucocorticoids
during neutropenia, respectively. The
oddsratioforbloodstreaminfectioncom-
paring subjects with a mean glucose of
200 vs. 100 mg/dl was 8.5 (2.4–30.2) if
glucocorticoids were received and 4.0
(1.4–11.2) if they were not (Fig. 1B). The
effect of preneutropenia glycemia on
bloodstream infections due to gram-
negative bacteria only was not signiﬁcant
(1.02 [0.90–1.17]). In a sensitivity anal-
ysis, we found all our results to be mini-
mally changed when the primary
exposure variable, mean preneutropenia
glucose, was calculated using central lab-
oratory plasma glucose results only and
no point-of-care measurements.
Stratiﬁcation for diabetes history
Among 25 patients with previously iden-
tiﬁed diabetes, 9 (36%) were diagnosed
with any infection and 7 (28%) were di-
agnosed with bloodstream infections. A
history of prior diabetes was indepen-
dently associated with any infection and
bloodstream infections with an adjusted
odds ratio of 2.48 (95% CI 1.01–6.13)
(P  0.049) and 3.30 (1.22–8.93) (P 
0.018), respectively. Given that only six
patients with prior diabetes received glu-
cocorticoids during neutropenia, the in-
teraction between mean preneutropenia
glucose and glucocorticoids could not be
tested within the diabetic subgroup. Dia-
betes history was not related to longer
length of stay, critical status designation,
orin-hospitalmortalityinthispopulation
with a low prevalence of diabetes.
Of 357 patients without previously
diagnoseddiabetes,65receivedglucocor-
ticoids during neutropenia. In these glu-
cocorticoid-treated patients, but not in
subjects not receiving glucocorticoids,
mean glucose was signiﬁcantly associated
with developing neutropenic infections
after adjustment; for every 10 mg/dl in-
crease in mean preneutropenia glucose,
the adjusted odds ratio was 1.17 (95% CI
1.02–1.34) (P  0.027) for any infection
and 1.19 (1.02–1.38) (P  0.029) for
bloodstream infections.
CONCLUSIONS — Many studies
(6–8) have reported an increased risk of
infections in outpatients with diabetes;
here,wedemonstratethatin-hospitalgly-
cemia is also related to the incidence of
nosocomial infections in a susceptible in-
patient population. We report that even
relatively mild, preexisting hyperglyce-
mia was associated with increased infec-
Table 1—Mean preneutropenia glucose according to demographic and clinical characteristics
Characteristic n (%)
Mean preneutropenia
glucose median
(interquartile range) P value
Age 0.0001
50 years 194 (51) 105 (97–115)
50 years 188 (49) 111 (102–128)
Sex 0.181
Male 223 (58) 108 (101–122)
Female 159 (42) 107 (98–119)
Race 0.630
White 315 (82) 108 (100–120)
African American 51 (13) 109 (99–125)
Other 16 (5) 109 (102–132)
Diabetes 0.0001
Yes 25 (7) 172 (136–203)
No 357 (93) 107 (100–117)
Type of cancer 0.096
Aggressive non-Hodgkin’s lymphoma 117 (31) 109 (101–126)
Indolent non-Hodgkin’s lymphoma 56 (15) 105 (101–120)
Hodgkin’s lymphoma 57 (15) 103 (94–117)
Multiple myeloma 35 (9) 113 (99–126)
Acute Leukemia 82 (21) 109 (103–121)
Chronic leukemia 23 (6) 103 (98–115)
Myelodysplastic syndrome 10 (3) 111 (108–115)
Other 2 (0.5) 125 (113–136)
Type of BMT 0.064
Autologous 225 (59) 109 (101–126)
Matched sibling 134 (35) 106 (99–116)
Matched unrelated 23 (6) 109 (99–114)
Glucocorticoid treatment after
neutropenia onset
0.120
Yes 71 (19) 107 (100–120)
No 311 (81) 111 (103–127)
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BMT. This relationship was particularly
prominent in patients who received glu-
cocorticoids while neutropenic. In
these patients, the association remained
signiﬁcant even after excluding patients
with prior diabetes who experienced
the most hyperglycemia.
Acute, short-term hyperglycemia af-
fects all major components of innate im-
munity and impairs the ability of the host
to combat infection (9). Hyperglycemia is
well known to adversely impair neutro-
phil activity, including chemotaxis, for-
mation of reactive oxygen species, and
phagocytosis of bacteria (10), but these
effects may be less deleterious in BMT pa-
tients who are already neutropenic. How-
ever, hyperglycemia also affects other
components of the immune system, thus
providing ample mechanisms for the ob-
served association between hyperglyce-
mia and neutropenic infections. The
diabeticstateincreaseslymphocyteapopto-
sis (11) and suppresses the proliferation of
T-cells due to decreased expression of
adenosine kinase (12). Also, the function
of immunoglobulins and complement is
attenuated due to their glycosylation in
the setting of hyperglycemia (13,14). Fi-
nally, hyperglycemia may promote the
exponential growth of bacteria and in-
crease the virulence of bacteria (15). For
example, detectable levels of glucose in
bronchial aspirates, observed in hyper-
glycemic but not normoglycemic pa-
tients, correlates with the presence of
pathogenic bacteria (15).
The relationship between glycemia
and infections has rarely been studied in
oncology patients, though it is a particu-
larly relevant question for this population
given their immunocompromised state
and increased risk for hyperglycemia sec-
ondary to frequent glucocorticoid use. A
recent study (16) from Japan failed to de-
tect an effect of hyperglycemia on infec-
tion during BMT. They had, however, a
far smaller sample size and a paucity of
glucose measurements compared with
our study. In addition, they did not ana-
lyze mean glycemia as a continuous vari-
able, and glycemia was evaluated during
neutropenia,raisingthequestionofcause
andeffect.AnotherstudyinBMTpatients
reportedthattotalparenteralnutritionin-
creasedtheadjustedoddsratioforinfection
to 2.2 (95% CI 1.4–3.5), a relationship
that became insigniﬁcant after correction
for mean glucose (17). This suggests that
the association between total parenteral
nutrition and infections may have been
driven by total parenteral nutrition–
induced hyperglycemia. Finally, a study
of patients with acute lymphocytic leuke-
mia undergoing induction chemotherapy
(not BMT) did show a relationship be-
tweenin-hospitalhyperglycemia(deﬁned
Table 2—Unadjusted association between mean glucose and major clinical outcomes
Outcome n (%)
Mean preneutropenia
glucose median
(interquartile range) P value
Any infection 0.014
Yes 84 (22) 111 (103–130)
No 298 (78) 107 (99–119)
Bloodstream infection 0.007
Yes 52 (14) 114 (103–134)
No 330 (86) 107 (99–119)
Pneumonia 0.318
Yes 29 (8) 111 (103–126)
No 353 (92) 108 (100–120)
Urinary tract infection 0.136
Yes 8 (2) 116 (109–134)
No 314 (98) 108 (100–120)
Clostridium difﬁcile colitis 0.275
Yes 12 (3) 112 (106–128)
No 370 (97) 108 (100–120)
Sinusitis 0.210
Yes 5 (1) 99 (96–109)
No 377 (99) 108 (100–121)
Long hospital stay* 0.734
Yes 287 (75) 108 (100–116)
No 95 (25) 108 (100–121)
Critical status 0.240
Yes 15 (4) 111 (99–125)
No 367 (96) 108 (100–125)
In-hospital death 0.728
Yes 13 (3) 113 (104–125)
No 369 (97) 108 (100–120)
*Long hospital stay is deﬁned as 75th percentile (28 days).
Table 3—Adjusted odds ratio (95% CI) for complications associated with every 10 mg/dl increase in mean glucose between admission and
neutropenia
Complication All subjects
Glucocorticoids administered during neutropenia
No Yes
n 382 311 71
Any infection (n  84) 1.11 (1.01–1.21); P  0.023 1.08 (0.98–1.19); P  0.136 1.21 (1.09–1.33); P  0.00001
Bloodstream infection (n  52) 1.17 (1.06–1.30); P  0.002 1.15 (1.03–1.28); P  0.010 1.24 (1.11–1.38); P  0.00001
Long hospital stay (n  92)* 0.96 (0.85–1.09); P  0.535 0.89 (0.78–1.02); P  0.094 1.08 (0.95–1.23); P  0.229
Critical status (n  15) 0.69 (0.42–1.13); P  0.141 0.80 (0.61–1.06); P  0.119 1.03 (0.84–1.28); P  0.752
In-hospital death (n  13) 1.08 (0.88–1.33); P  0.447 0.84 (0.64–1.11); P  0.213 1.13 (0.92–1.40); P  0.224
Adjusted for age, sex, race, cancer diagnosis, transplant type, year of transplant, and cumulative glucocorticoid dose before neutropenia onset. *Long hospital stay
is deﬁned as 75th percentile (28 days).
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200 mg/dl) and infections (relative risk
for any infection of 1.28) (P value 
0.009) (1).
Similar to results reported by Garg et
al. (18), our data demonstrate a positive
association between hospital length of
stay and mean glucose readings per-
formed throughout the entire course of
BMT (P value 0.0001). However, when
we focused on the preneutropenic period
(before infection onset), we found that
hyperglycemiawasnotassociatedwithan
increased length of stay (P  0.351).
Thus, it is likely that the association be-
tween higher mean glucose based on all
hospital glucose values and longer length
of stay is not causal but is observed be-
causebothresultfrommoresevereillness
during neutropenia.
A main strength of our study is the
studydesign,inwhichglycemicexposure
was ascertained during a period of time
when infections and other complications
were not present, thereby increasing our
ability to speculate that a causal relation-
ship exists between hyperglycemia and
infections.Asecondstrengthisouranalysis
of the interaction between hyperglycemia
andglucocorticoiduseoninfections.While
glucocorticoids are known to increase
infection rates (19), the extent to which
glucocorticoids modify the effect of hy-
perglycemia on infections has never be-
fore been examined.
Our study has some limitations. As
with all observational studies, it is possi-
ble that unmeasured confounders affected
the associations observed. However, we
suspect such an effect would be minimal
since we were able to adjust for many po-
tential confounders and patients were
otherwiserelativelysimilarbeforeneutro-
penia. Because the BMT population is rel-
atively young and the prevalence of prior
diabetes in our population was low, we
were unable to evaluate whether the extent
of hyperglycemia in patients with diabetes
inﬂuencesinfectionrates.Furthermore,in
subjectswithoutpreviouslydiagnoseddi-
abetes, the lack of signiﬁcant variation in
preneutropenia mean glycemia likely de-
creasedourabilitytodetectanassociation
between glycemia and infections in this
subgroup unless glucocorticoids were re-
ceived.Additionally,ourpowertodetectan
effect of hyperglycemia on other outcomes
(nonbloodstream infections, critical status
designation, and death) was diminished by
the low incidence of these outcomes in our
study group.
In conclusion, our results suggest an
important association between preneu-
tropenia hyperglycemia and neutropenic
infection rates during BMT, especially
prominent in patients who receive glu-
cocorticoids during neutropenia. The
magnitude of this association is compara-
ble with those seen with commonly uti-
lized strategies for infection prevention
during BMT, such as the use of prophy-
lactic antibiotics, protective isolation,
andhigh-efﬁciencyparticulateairﬁlters
(20–23).Ourﬁndingssupporttheneed
Figure 1—A: Predicted odds ratios for any infection for increasing mean preneutropenia glucose
compared with a mean glucose of 100 mg/dl. B: Predicted odds ratios for bloodstream infection.
(Œ), glucocorticoids received during neutropenia (n  71); (f), glucocorticoids not received
during neutropenia (n  311). Odds ratios were calculated using multivariate logistic regression
models, which included age, sex, race, cancer diagnosis, transplant type, year of transplant, and
cumulativeglucocorticoiddosebeforeneutropeniaonset.Thevalueschosenforthecovariateswere
the median in the case of continuous variables and the most frequent category in the case of
categorical variables.
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sive glycemic control improves infec-
tionratesinBMTpatientsandotherhigh-
risk populations.
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